| Journal of Pharmaceutical Policy and Practice | |
| The use of remdesivir outside of clinical trials during the COVID-19 pandemic | |
| Armond Daci1  Aleksandar Dimovski2  Vesa Halimi2  Aleksandra Grozdanova2  Venko Filipce3  Irina Panovska-Stavridis4  Nevenka Ridova4  Milena Stevanovic5  | |
| [1] Department of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo;Faculty of Pharmacy, University Ss. Cyril and Methodius University, Skopje, North Macedonia;University Clinic for Neurosurgery, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia;University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius University, Skopje, North Macedonia;University Clinic of Infection Diseases and Febrile Conditions, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia; | |
| 关键词: COVID-19; Remdesivir; Clinical practice; Clinical trials; Expanded access; Compassionate use; Early access scheme; Emergency use; Conditional approval; | |
| DOI : 10.1186/s40545-020-00258-8 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and investigated through clinical research (clinical trials) and clinical practice (compassionate use, expanded access, early access scheme, and emergency use). Currently, remdesivir approval status differs between states. This paper aims to review and analyze regulatory approaches for accessing and investigating remdesivir, by communicating regulatory variability between countries in terms of terminology, modalities, and protocols.
【 授权许可】
CC BY
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202104249318975ZK.pdf | 360KB |
PDF